Regencell Bioscience Holdings Limited RGC
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 83.20% | 26.21% | -25.40% | -22.97% | -22.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.01% | 19.29% | -20.41% | -17.39% | -14.61% |
| Operating Income | -62.01% | -19.29% | 20.41% | 17.39% | 14.61% |
| Income Before Tax | -74.86% | -26.67% | 17.85% | 18.08% | 18.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.86% | -26.67% | 17.85% | 18.08% | 18.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -120.35% | -125.97% |
| Net Income | -72.39% | -26.72% | 16.68% | 14.86% | 13.20% |
| EBIT | -62.01% | -19.29% | 20.41% | 17.39% | 14.61% |
| EBITDA | -66.52% | -22.87% | 18.42% | 16.58% | 14.23% |
| EPS Basic | -69.05% | -24.42% | 18.18% | 15.22% | 12.50% |
| Normalized Basic EPS | -58.62% | -52.17% | -41.18% | -51.43% | -61.11% |
| EPS Diluted | -69.05% | -24.42% | 18.18% | 15.22% | 12.50% |
| Normalized Diluted EPS | -58.62% | -52.17% | -41.18% | -51.43% | -61.11% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |